FATE:NSD-Fate Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.34

Change

-0.08 (-5.63)%

Market Cap

USD 0.14B

Volume

0.80M

Analyst Target

USD 39.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.03 (-0.46%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.86 (-0.38%)

USD 65.38B
ARGX argenx NV ADR

+7.09 (+1.24%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+0.88%)

USD 32.75B
ONC BeiGene, Ltd.

-1.27 (-0.49%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.31 (+0.93%)

USD 18.35B
SMMT Summit Therapeutics PLC

+0.17 (+0.87%)

USD 13.53B
INSM Insmed Inc

-0.95 (-1.29%)

USD 11.84B
INCY Incyte Corporation

-0.18 (-0.27%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.84 (-1.50%)

USD 11.29B

ETFs Containing FATE

CNCR Loncar Cancer Immunothera.. 2.15 % 0.79 %

N/A

USD 6.95M
WDNA:LSE WisdomTree BioRevolution .. 1.82 % 0.00 %

-0.05 (-0.36%)

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.79% 52% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.79% 52% F 31% F
Trailing 12 Months  
Capital Gain -64.74% 27% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.74% 27% F 12% F
Trailing 5 Years  
Capital Gain -95.25% 25% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.25% 25% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -32.20% 14% F 7% C-
Dividend Return -32.20% 14% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.33% 51% F 27% F
Risk Adjusted Return -48.55% 25% F 17% F
Market Capitalization 0.14B 55% F 43% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector